Sentences with word «lorcaserin»

In the first study of the drug lorcaserin in the human brain, the research revealed the mechanism underlying the drug's efficacy and provides insight into which individuals may benefit most from the medication.

The U.S. Food and Drug Administration today approved lorcaserin hydrochloride as a weight - loss drug, according to MedPage Today.

Dr. Baraban and his colleague Kelly Knupp, M.D. at the University of Colorado, Denver, then tested lorcaserin in five children with Dravet syndrome.

The European Medicines Agency reported that it was unlikely to approve lorcaserin because of concerns about possible cancers, psychiatric disorders and heart valve problems, prompting the manufacturer to withdraw its application.

Lorcaserin targets only a very specific serotonin receptor (known as 5 - HT2c), shown in animal studies to play a role in abnormal food consumption.

Effects of lorcaserin (Belviq ®) on nicotine - and food - maintained responding in non-human primates Jacobs DS, Barkin CE, Kohut MR, Bergman J, Kohut SJ.

The trials showed that randomization to either drug, in addition to a calorie - restricted diet and increased exercise, was associated with more weight loss than patients» randomization to placebos (3 percent more weight loss with lorcaserin; 7 percent more with phentermine / topiramate).

«We wanted to find out if lorcaserin was acting on these brain regions and, if so, where and how.

The data also revealed that subjects who had the strongest brain responses to food prior to taking lorcaserin saw the most success with the weight - loss medication.

In a study published this week in the New England Journal of Medicine, nearly 50 % of the people on lorcaserin lost at least 5 % of their body weight after using it for a year, compared with about 20 % of those on placebo.

(Dr. Ryan served as a consultant to the manufacturers of Qnexa and lorcaserin prior to January 2008.)

Lorcaserin activates serotonin receptors in the body that regulate hunger to suppress your appetite.

Approved by the FDA in 2012, the generic drug lorcaserin is a medication prescribed for obese or overweight adults who also have weight - related health complications such as diabetes.

In 2012, though, the FDA approved two drugs for long - term weight loss, lorcaserin hydrochloride (Belviq; Eisai Inc) and phentermine / topiramate (Qsymia; Vivus Inc).

«Lorcaserin targets important brain hormones called pro-opiomelanocortin (POMC) peptides, which are responsible for regulating appetite.

The Food and Drug Administration refused to approve two investigational appetite suppressants, Qnexa and lorcaserin, primarily out of safety concerns.

At Week 4, the lorcaserin group in the fed state showed less activity in the parietal cortex — which is responsible for integrating sensory information — when looking at any of the food images.

Lorcaserin could produce weight loss without these cardiac risks, the authors noted.

«Decreases in caloric intake, weight, and BMI were linked to strong responses to food cues in the areas of the brain related to emotion, pleasure and attention prior to taking the weight - loss drug, which suggests that lorcaserin could prove to be of particular benefit to»em otional eaters,»» Mantzoros said.

Belviq (lorcaserin) is no wonder drug, but it can help people to lose about 3 — 4 % of their body weight when combined with a healthy diet and exercise.

Endowed Chair in Neuroscience Research and professor of neurological surgery at the University of California, San Francisco (UCSF), postdoctoral fellow Aliesha Griffin, Ph.D., and colleagues used a zebrafish model of Dravet syndrome to test the drug lorcaserin and found that it suppressed seizure activity in the fish.

Lorcaserin was initially associated with decreased seizure frequency in all of the children.

The researchers next identified a comparable drug, lorcaserin, which also affects the serotonin system and is available for clinical use.

«We have discovered that this obesity drug, lorcaserin, acts in the brain to improve type 2 diabetes.

It follows research into obesity drug lorcaserin, which modifies brain activity to regulate appetite and help with weight loss.

In the last year, the FDA has declined to approve three new diet medications, Qnexa, lorcaserin, and Contrave, citing concerns ranging from potential birth defects to heart risks to cancer.

A Food and Drug Administration (FDA) panel is meeting on Thursday to discuss one of the drugs, Qnexa, and the panel is scheduled to consider two more drugs, lorcaserin and Contrave, in the coming months.

Lorcaserin, the second drug scheduled for FDA review, works by stimulating serotonin receptors in the brain, just as Pondimin and Redux did.

Other treatment options for obesity include certain prescription and over-the-counter medications that curb appetite, such as orlistat and lorcaserin, but the drugs can cause side effects, such as cramping, diarrhea, headaches, dizziness and nausea.

By attempting to control your appetite, the theory is that lorcaserin will allow you to feel full even after having eaten less food.

In fact, many of these prescriptions — including those containing — lorcaserin, liraglutide, and a combination of phentermine and topiramate — require a Body Mass Index (BMI) higher than 30 or a BMI of 27 and higher along with a weight - related medical condition, like type 2 diabetes or high blood pressure.

Those hoping to take Belviq (lorcaserin hydrochloride) who have a BMI less than 30 must also have a weight related condition such as high cholesterol, high blood pressure, or diabetes.

Stacy Weigman, Pharmaceutical Doctorate, comments, «Taking Belviq (lorcaserin) may help you keep weight off after you've lost it, although taking it isn't a guarantee.

Lorcaserin (Belviq) is a weight loss drug approved by the FDA within the last month.

A Food and Drug Administration panel is meeting on Thursday to discuss one of the drugs, Qnexa, and the panel is scheduled to consider two more drugs, lorcaserin and Contrave, in the coming months.

In October, the U.S. Food and Drug Administration (FDA) nixed not one but two new weight - loss drugs, lorcaserin and Qnexa, because of possible links to cancer (lorcaserin) and heart problems (Qnexa).